
--- Page 1 ---
UUID: EA8A0A91-7A83-4EC9-B7A0-0C3300D1FD14E TCGA-XX-A899-01A-PR zeiDD Redacted iyyustolirg dolulor areensro N6 s 8s20|3 cs0.9 Research Gross Description J0s08 year old female multifocal breast cancer Research Dx Procedure: Total mastectomy (including nipple and skin) Lymph node sampling: Sentinel Iymph node and axillary dissection Specimen laterality: Right Tumor site: Multifocal, lower outer quadrant (majority of tumors) and lower inner quadrant Tumor size: 2 x 1.5 x 1.3 cm (largest tumor) Histopathologic type: Lobular with foci of signet ring morphology 0% on +op sfide. Histopathologic grade (Nottingham): 2 Mitotic count: 2 mitoses/10 hpf (low proliferative rate) Tumor focality: Multiple foci of invasive carcinoma Pathologic tumor stage: pT1c: Tumor greater than 1 cm but less than or equal to 2 cm in greatest dimension Margin status: See below Distance of carcinoma from margins: Anterior: 0.35 mm (microscopic focus) Posterior: 8 mm. All other margins greater than 1 cm Associated in situ carcinoma: Yes Type: LCIS Extensive (>25% of total tumor): No.  Separate (extra-tumoral) foci away from main lesion: Yes Peritumoral angiolymphatic invasion: Not identified Dermal angiolymphatic invasion: Not identified  Hormone receptors by properly controlled immunohistochemistry performed on previous core biopsy Estrogen receptor: Positive Progesterone receptor: Positive HER-2/neu (ERBB2): Negative Pathologic lymph node stage: pN2a: Metastasis in 4-9 axillary lymph nodes (at least one tumor deposit greater than 2.0 mm) Number of nodes positive for metastasis/total number nodes sampled: 5/22 Maximum diameter of largest lymph node metastasis: 1 cm Extranodal extension by tumor: Present, focal. Distant metastasis: pM: Not applicable. Additional pathologic findings: Fibrocystic changes AJCC Staging (7th Edition): pT1c(m) pN2a pM: Not applicable Research QC Tumor: 80% tumor nuclei 0% necrosis 20% normal Normal: 100% breast

--- Page 2 ---
Specimen Process Time Blood draw time: Plasma frozen time: Serum frozen time: Buffy coat frozen time Cold ischemia start time: Formalin fixation start time: Total cold ischemia time: Formalin fixation stopped time: Total formalin fixation time: Specimen Weight  Normal 1-512 mg, 2-351 mg, 3-283 mg, 4-372 mg Tumor 1-262 mg, 2-205 mg, 3-208 mg, 4-317 mg Specimen Size Plasma x 3 Serum x 2 Buffy coat x 1 Cryovials x 8. Normal x 4 Tumor x 4: 1-2 lesion site A., 3-4 lesion site B. FFPE x 8 Normal x 4 Tumor x 4: 1-2 lesion site A., 3-4 lesion site B. Study Patient Consent Yes HPAA Discrepancy ual/Synchron aeis (circie): 2

--- Page 3 ---
Page 1 of 1 TCGA Pathologic Diagnosis Discrepancy Form 4.05  Study Subject ID: Person ID: N/A Study/Site: TCGA Breast Invasive Carcinoma - (Breast Invasive Carcinoma) Age: N/A Event: PathDiscrepancy Date of Birth: Interviewer: Sex: F Tumor Identifier Provided on Initial Case.  Provide the tumor identifier documented on the initial case quality Quality Control Form control form for this case.  Pathologic Diagnosis Provided Infiltrating lobular Provide the diagnosis/ histologic subtype(s) documented on the initial on Initial Pathology Report. carcinoma pathology report for this case. If the histology for this case is mixed, provide all listed subtypes. Histologic features of the sample provided for signet ring Provide the histologic features selected on the TCGA Case. TCGA, as reflected on the CQCF  morphology Quality Control Form completed for this case..  Discrepancy between Pathology Report and Case Quality Control Form Provide the reason for the pathology report reports the presence Provide a reason describing why the diagnosis on discrepancy between the pathology of signet ring morphology, however, the initial pathology report for this case is not report and the TCGA Case Quality the topslide contains 0% signet ring. consistent with the diagnosis selected on the TCGA Controi Form Case Quality Control Form.  Name of Tss Reviewing Pathologist or Provide the name of the pathologist who reviewed this. Biorepository Director case for TCGA.